Tzofnat Farbstein-Aljanati, Tal Tirosh-Wagner, Ivan Budnik, Uriel Katz, Sharon Borik, Assaf A Barg, Gili Kenet, Sarina Levy-Mendelovich
{"title":"Intracardiac thrombi in children: A decade of experience at a tertiary care hospital.","authors":"Tzofnat Farbstein-Aljanati, Tal Tirosh-Wagner, Ivan Budnik, Uriel Katz, Sharon Borik, Assaf A Barg, Gili Kenet, Sarina Levy-Mendelovich","doi":"10.1080/08880018.2025.2531011","DOIUrl":null,"url":null,"abstract":"<p><p>Intracardiac thrombus (ICT) in children is a serious and potentially life-threatening condition, particularly among hospitalized patients. Pediatric-specific data on ICT remain scarce, posing challenges for optimal, evidence-based management. This study aimed to analyze pediatric ICT cases over a decade to identify clinical characteristics, management strategies, and outcomes.</p><p><p>This retrospective study was conducted at a tertiary referral center and included all pediatric patients (ages 0-18) diagnosed with ICT between 2012 and 2023. Clinical and demographic data were extracted from electronic medical records, following IRB approval.</p><p><p>Twenty-three children were identified (median age: 39 months; 52% female). Major risk factors included central venous catheters (60.9%), congenital or acquired heart disease (52.2%), and malignancy (34.8%). Most thrombi (78.3%) were right-sided. ICT was incidentally diagnosed in 56.5% of cases; in others, symptoms led to imaging <i>via</i> echocardiography, CT, or cardiac catheterization.</p><p><p>Anticoagulation therapy was initiated in 87% of patients. Eight required indefinite treatment due to persistent thrombi or ongoing risk factors, while others received a median therapy duration of four months. Three patients did not receive anticoagulation due to clinical considerations. Surgical thrombectomy was performed in four cases (17.4%), and one patient underwent catheter-based thrombolysis. There were no major bleeding events. Complete thrombus resolution was achieved in 60.9% of cases, with partial improvement in 26.1%.</p><p><p>ICT in children is associated with identifiable risk factors and is commonly managed with anticoagulation. Surgical or interventional procedures may be needed in select cases. Early identification of high-risk patients is essential to improve outcomes.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"323-332"},"PeriodicalIF":1.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2025.2531011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Intracardiac thrombus (ICT) in children is a serious and potentially life-threatening condition, particularly among hospitalized patients. Pediatric-specific data on ICT remain scarce, posing challenges for optimal, evidence-based management. This study aimed to analyze pediatric ICT cases over a decade to identify clinical characteristics, management strategies, and outcomes.
This retrospective study was conducted at a tertiary referral center and included all pediatric patients (ages 0-18) diagnosed with ICT between 2012 and 2023. Clinical and demographic data were extracted from electronic medical records, following IRB approval.
Twenty-three children were identified (median age: 39 months; 52% female). Major risk factors included central venous catheters (60.9%), congenital or acquired heart disease (52.2%), and malignancy (34.8%). Most thrombi (78.3%) were right-sided. ICT was incidentally diagnosed in 56.5% of cases; in others, symptoms led to imaging via echocardiography, CT, or cardiac catheterization.
Anticoagulation therapy was initiated in 87% of patients. Eight required indefinite treatment due to persistent thrombi or ongoing risk factors, while others received a median therapy duration of four months. Three patients did not receive anticoagulation due to clinical considerations. Surgical thrombectomy was performed in four cases (17.4%), and one patient underwent catheter-based thrombolysis. There were no major bleeding events. Complete thrombus resolution was achieved in 60.9% of cases, with partial improvement in 26.1%.
ICT in children is associated with identifiable risk factors and is commonly managed with anticoagulation. Surgical or interventional procedures may be needed in select cases. Early identification of high-risk patients is essential to improve outcomes.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.